Investigational drug · Phase 2
NST-6179
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Intestinal Failure Associated Liver Disease.
Phase 2Last checked: Nov 20, 2026Latest source record: Jan 7, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "NST-6179"
First trial start
2024
Jan 15, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NST-6179", any sponsor or status.
Conditions studied
As listed on its trial records.
- Intestinal Failure Associated Liver Disease
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "NST-6179" as an intervention, largest first.
NorthSea Therapeutics B.V.Industry
NCT05181085 · 70 participants · Start Nov 11, 2021 · Primary completion May 27, 2022
Drug: NST 6179; Placebo · For: Short Bowel Syndrome; Parenteral Nutrition Associated Liver Disease
Sites: Leeds, United Kingdom
NorthSea Therapeutics B.V.Industry
NCT05919680 · 36 participants (planned) · Start Jan 15, 2024 · Primary completion Jun 30, 2025
Drug: NST-6179 Part A; NST-6179 Part B · For: Intestinal Failure Associated Liver Disease
Sites: Scottsdale, Arizona; San Francisco, California; Washington D.C., District of Columbia · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.